To evaluate the impact of high altitude on cardiac morphology and function in patients with coronary artery disease (CAD) and healthy controls.
Aims
To evaluate the impact of high altitude on cardiac morphology and function in patients with coronary artery disease (CAD) and healthy controls.
Methods and results
Eight patients with a history of acute myocardial infarction [53 + 8 years, left ventricular (LV) ejection fraction 54 + 6%] and a low risk score were compared with seven healthy controls (41 + 16 years) during the Dutch Heart Expedition 2007 at the Aconcagua (6960 m) in Argentina. An exercise test and echocardiography were performed at sea level and at base camp (4200 m). In the apical four-chamber view, right ventricular (RV) diameter, tricuspid annular plane systolic excursion (TAPSE), early transmitral inflow peak velocity (E), atrial transmitral inflow peak velocity (A), and peak tissue velocity during early diastole (E 0 ) were obtained. Changes in global LV function and wall motion score index (WMSI) were used as markers of ischaemia. There were no significant differences in individual global LV function and WMSI at high altitude compared with sea level in both groups. A significant increase in RV diameter was observed in the patient group at 4200 m compared with sea level and a trend towards the same result in the control group. A decrease in TAPSE was observed. Measurements of the E 0 showed a significant decrease in the LV septum and lateral wall at high altitude compared with sea level in both groups.
Conclusion
Symptoms and echocardiographic signs of myocardial ischaemia were absent in low-risk patients with a history of CAD during and after exercise up to an altitude of 4200 m. Patients and healthy controls showed comparable changes at high altitude compared with sea level with an increase in RV diameter, a decrease in TAPSE, and decreased E
Introduction
As the number of patients with coronary artery disease (CAD) exposed to high altitude through recreational activities such as climbing has increased substantially in recent decades, physicians are faced with the difficult task of informing and advising these patients on safety. Furthermore, evidence-based recommendations are made more difficult by the sparse amount of published reports on this topic. Studies done in healthy individuals demonstrated that the normal cardiovascular response to short-term high-altitude exposure includes immediate increases in heart rate, blood pressure, cardiac output, and ventilation. 1, 2 While vasodilatation occurs in the coronary arteries with an increase in coronary blood flow, a swift increase in pulmonary artery pressure is observed which is thought to be caused by hypoxia-induced pulmonary vasoconstriction. This may lead to right ventricle (RV) pressure overload and a change in left ventricular (LV) diastolic function. 3 Pulmonary hypertension may subsequently lead to the development of subclinical or manifest high-altitude pulmonary oedema, even in healthy climbers after a modest climb.
2
After long-term high-altitude exposure, acclimatization occurs and is associated with a lower blood pressure and lower cardiac output as well as other physiological compensatory mechanisms including an increase in red blood cell mass by erythropoietin and a reduction in the alveolar-arterial oxygen gradient. 4 However, it is less well established if such adaptation mechanisms will suffice at high altitudes above 3500 m in patients with CAD, and which possible haemodynamically relevant changes occur in the cardiovascular system. Accordingly, we investigated the effect of long-term high-altitude exposure on cardiac morphology and function in low-risk patients with a history of myocardial infarction in comparison to healthy controls.
Methods

Study population
The study population comprised eight patients with a history of acute myocardial infarction (seven males, one female), with a mean age of 53 + 8 year, and seven healthy subjects (four males, three females, 41 + 16 yr). Patients willing to participate were recruited in the Netherlands via an advert in a patient magazine. Exclusion criteria were age .65 years, left ventricular ejection fraction (LVEF) ,45%, uncontrolled systemic hypertension (.160/95 mmHg at rest), documented ventricular tachycardia, moderate to severe valvular disease, and functionally relevant neurologic, pulmonary, or nephrologic diseases. Of the 50 patients who applied, eight patients were participating in this study at 2-12 years after the acute event (mean 5.6 + 3.6 years). The participating eight patients all had significant single-vessel disease (five of eight left anterior descending artery, three of eight right coronary artery). Seven patients were previously treated by percutaneous coronary intervention and one patient was treated conservatively. The healthy controls were all members of the expedition, including expedition leader and organizers. The controls performed the same tests as the patients prior to the expedition.
All participants were informed about the possible risks and officially gave their voluntary written consent.
Study protocol
A symptom-limited cardiopulmonary exercise test was performed in all patients at sea level in the Isala Clinics, Zwolle, the Netherlands, in November 2006 and during the Dutch Heart Expedition at base camp on M. Aconcagua (4200 m) in Argentina in March 2007 after a 2-week period of acclimatization. The first week of acclimatization was at Vallecitos in the Andes at altitudes between 1800 and 4200 m. In the second week, base camp of M. Aconcagua (4200 m) was reached through the Vacas Valley. The summit attempt was planned for the third week. The use of b-blockers was not discontinued during the study for safety reasons and to retain comparability of the results between different altitudes. Echocardiographic examinations were performed before and after the symptom-limited cardiopulmonary exercise stress test at sea level and at base camp after 10 days of acclimatization. All acquisitions were made by a qualified and experienced cardiac sonographer with a portable Vivid I ultrasound system (GE Ultrasound) equipped with tissue Doppler technology. Care was taken to ensure that the position of the subjects and the transducer were similar in all examinations. In the apical four-chamber view, RV diameter, tricuspid annular plane systolic excursion (TAPSE), early transmitral inflow peak velocity (E), and atrial transmitral inflow peak velocity (A) were obtained. Colour-coded tissue Doppler imaging was used to assess peak tissue velocity during early diastole (E 0 ) at three locations: LV septum and lateral wall, and RV annulus. Ejection fraction was calculated by the summation of discs method (biplane Simpson's rule) from the apical two-and fourchamber view. The global and segmental wall motion was evaluated by an independent echocardiographer experienced in the interpretation of stress-echo images using a semi-quantitative scoring index with a 16-segment model. 5 Changes in global LV function and wall motion score index (WMSI) were used as markers of ischaemia.
Statistical analyses
Continuous variables are expressed as mean + SD. Categorical variables are presented as absolute numbers and percentages. The data were analysed using standard statistical software (SPSS). For comparison between data at sea level and base camp, the Wilcoxon signed-rank test was used. For comparison between the groups, the Mann -Whitney U-test was used. A value of P , 0.05 was considered statistically significant.
Results
The baseline characteristics of the patient group and the healthy controls are described in Table 1 . None of the participants of this study had overt symptoms of ischaemia or heart failure during the study period and no adverse events occurred. Haemodynamic and echocardiographic measurements in patients and controls at sea level and high altitude are described in Table 2 . No significant differences were observed in individual global LV function at high altitude compared with sea level in both the patient and the control groups ( Table 2) . Furthermore, the WMSI did not change significantly at high altitude compared with sea level in both groups, although in three participants of the patient group, hypokinesia was observed in two previously normokinetic segments.
There was a significant increase in RV diameter in the patient group at high altitude compared with sea level and a trend towards the same result in the control group (Figure 1) . This RV dilation occurred with a significant decrease in TAPSE at base camp compared with sea level in both groups (Figure 2) . However, no significant difference in TAPSE between the patient group and the healthy controls was observed ( Table 2) .
The rest-E/A ratio decreased in both groups at 4200 m compared with sea level, although statistical significance was not reached. A significant decrease in peak tissue velocity during early diastole of the LV septum and lateral wall was observed at higher altitude in the patient and control groups, respectively. However, the E/E 0 ratio stayed within normal range for both groups. Finally, measurements of E 0 at the RV annulus did not show a significant change at high altitude compared with sea level in the patient group and the healthy control group ( Table 2) . 
Discussion Cardiac morphology and function
Few studies exist on echocardiographically determined cardiac alterations at high altitude in healthy subjects 3,6 -9 and to date none has been conducted specifically in patients with CAD. To our knowledge, this is the first study evaluating the impact of high altitude on changes in cardiac morphology and function in low-risk patients with CAD compared with healthy controls using tissue Doppler imaging at a real altitude of 4200 m. The results demonstrated a marked RV dilation in the patient group and healthy controls, which is associated with increased pulmonary arterial pressure that develops at high altitude by hypoxia-induced pulmonary vasoconstriction. In addition, the small but significant decrease in TAPSE accompanying the increase in RV diameter is a clear sign suggesting a tendency towards RV dysfunction at high altitude in both patients and healthy controls. A TAPSE ,20.1 mm is identified as abnormal RV function and an early indication of pulmonary hypertension. 10 Furthermore, our results showed a clear decrease in the E/A ratio (in rest and after exercise), while measurements of peak tissue velocity during early diastole demonstrated a significant decrease in the LV septum and lateral wall at higher altitude in the patient and control groups, respectively. Although not all results reached statistical significance due to the small study population, a trend towards mild diastolic dysfunction of the LV could be observed. These findings confirm earlier reports that demonstrated impairment of the RV and a change in LV diastolic function in healthy subjects. 3, 6, 7 An association between elevated pulmonary artery pressures and LV diastolic dysfunction has been proposed. 6, 11, 12 Owing to ventricular interdependence and pericardial constraint, RV pressure overload may cause a paradoxical interventricular septum shift towards the LV, delaying LV filling and reducing LV diastolic volume. 13 With subsequent reduction in LV filling pressure and dimensions, stroke volume and cardiac output fall. The findings of this study suggest that these changes in cardiac morphology and function do not differ substantially in low-risk patients with CAD compared with healthy controls and seem to be in the normal range of physiological adaptation to high altitude.
Safety and recommendations
No overt symptoms of ischaemia or heart failure were experienced by any of the participants during the climb to altitude or the exercise stress testing. Furthermore, no significant changes were observed in LV systolic function and WMSI as prespecified markers for ischaemia. The lack of symptomatology and echocardiographic signs of myocardial ischaemia in the patient group during and after exercise up to an altitude of 4200 m and the absence of adverse events during the study period are reassuring from the viewpoint of safety. There were also no cardiac events during the follow-up period of nearly 3 years (33 months). The limited number of other systematic studies in patients with CAD was performed at altitudes between 2500 and 3500 m, and patients were primarily subjected to acute high-altitude exposure without appropriate acclimatization. 14 -18 Despite these differences in methodology, the findings of these studies mainly seem to confirm that most patients with stable CAD and a normal exercise stress test at sea level can be advised to make the ascent without imposing any serious risk. Nonetheless, high-altitude exposure alone or in combination with exercise may unpredictably lead to another acute coronary syndrome, acute heart failure, and even death. In two studies, patients with CAD did show signs of worsening ischaemia at high altitude. In one study, exercise-induced coronary flow reserve decreased by 18% at an altitude of 2500 m. It should be noted that these patients were unacclimatized and had angiographically proven obstructive coronary lesions up to 90% at the time of ascent. 17 In another study, 20 veterans, of which 85% either with known CAD or at high risk for CAD, were studied at sea level, acute simulated altitude to 2500 m, and after 5 days of acclimatization to 2500 m. 19 An acute high-altitude exposure depressed the ischaemic threshold by 5% on the first day and one patient sustained a myocardial infarction after exercise at altitude. However, the authors note that this patient had a history of myocardial infarction, coronary artery bypass surgery, and chronic atrial flutter requiring treatment with digoxin, and retrospectively may have had symptoms of acute coronary insufficiency. Furthermore, the patient group was very heterogeneous and comprised much elder patients in comparison to our study. Ultimately, the authors concluded that patients with CAD who are sufficiently compensated at sea level do well at moderate altitude and acclimatize well with normalization of sea level performance after 5 days. 19 On the basis of previous reports and the findings of this study, patients with low-risk CAD can be advised to make an ascent to 3000-3500 m with minimal increased risk, provided that the exercise capacity at sea level is satisfactorily high and there are no concomitant illnesses impairing normal oxygenation of the blood. An individual evaluation of a patient's history, clinical status, and functional class as well as a consideration of the expected physical effort and stress of the journey are recommended. A slow ascent or an acclimatization period of 3-5 days seems reasonable alternatives to guard against worsening of angina. Nevertheless, if symptoms of ischaemia or heart failure do arise on ascent medication can help, but it should be noted that descent itself is the fastest and most efficient treatment.
The results of our study seem to suggest that adequately acclimatized patients with low-risk CAD may ascent to an altitude of 4200 m with minimal increased risk. However, the studied small sample size of patients may not be representative of the population as a whole. An appropriately powered prospective study with clinical endpoints is required to adequately establish the safety of stating the previous recommendations for patients with low-risk CAD ascending to an altitude of 4200 m, although a study like that will be logistically challenging.
We restricted our analysis to a low-risk patient group with a history of myocardial infarction at least 3 months after the acute event, a preserved LV ejection fraction without exercise-induced myocardial ischaemia at sea level. Besides this, care was taken that patients and controls were adequately acclimatized. The results of our study cannot be extrapolated to patients with intermediate to high risk CAD or to an acute ascent to 4200 m.
Conclusions
RV dilation and minor RV dysfunction occurred at high altitude in low-risk patients with CAD and healthy controls. In addition, a trend towards mild diastolic dysfunction of the LV could be observed. However, these alterations in cardiac morphology and function do not differ substantially between both groups and seem to be in the normal range of physiological adaptation to high altitude. A larger study with clinical endpoints is needed to establish the safety of expanding the previous recommendations to patients with low-risk CAD to ascending to 4200 m.
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